Currently Enrolling
RSV
Phase 2b
Study ID: 2402T1432

RSV Study

Sponsored by Shionogi

Official Study Title
A phase 2b, multicenter, randomized, double-blind, placebo controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of S-337395 in symptomatic non hospitalized adults with respiratory syncytial virus who are at high risk of progression to severe disease
Sponsor
Shionogi
Phase
Phase 2b
Indication
Respiratory Syncytial Virus (RSV)
Duration
12 months
About This Study

Objective

To investigate the PK of S-337395 in participants with RSV infection.

Who Can Participate

Key Eligibility Criteria

Below are the main inclusion and exclusion criteria for this study. The full eligibility assessment will be discussed with you by our research team during screening.

Key Inclusion Criteria

  • Adult participants (≥18 years)
  • New or worsening respiratory symptoms consistent with RSV (e.g., cough, fever, nasal congestion, shortness of breath)
  • Symptom onset within 72 hours prior to screening
  • RSV confirmed by PCR or molecular test or suspected RSV pending confirmation
  • Able and willing to undergo nasal/nasopharyngeal swabs
  • Able to provide informed consent

Key Exclusion Criteria

  • Hospitalized at screening or expected hospitalization within 24 hours
  • Recent COVID-19 or influenza infection (within 28 days)
  • Other respiratory infection (non-RSV) within 28 days
  • Receipt of RSV treatment (e.g., ribavirin) within 14 days
  • Recent systemic antiviral therapy
  • Recent RSV vaccination
  • Significant immunocompromised conditions (e.g., active cancer therapy, transplant, HIV)
  • Severe renal disease or dialysis
  • Active liver disease or clinically significant abnormal liver tests
  • Use of prohibited concomitant medications
Get Started

Apply for this study

Fill out the form below to see if you qualify. Our research coordinators will contact you directly to discuss your eligibility — there's no obligation to participate.

Your information is kept confidential and only used for study eligibility purposes.

Research team discussing clinical study data in laboratory
Why Participate

Advancing research, one participant at a time.

Clinical trials depend on volunteers like you. By participating, you gain access to potential new treatments while helping researchers discover safer, more effective therapies for everyone.

  • Access to investigational treatments and expert medical care
  • Close monitoring by our experienced research team
  • Contribute to better treatments for future patients
  • Confidential — your information is protected at every step